Clinical Trials
46 trialsNCT04250155 2026-05-26
An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
Phase 1 Active not recruiting
NCT04589845 2026-05-08
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT04896697 2026-05-05
Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid Tumors
Xilio Development, Inc.
Phase 1/2 Active not recruiting
NCT06031441 2026-05-04
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
Phase 1 Recruiting
NCT03228537 2026-05-01
Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT07190833 2026-04-09
A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients (South Korea)
Bionoxx Inc.
Phase 1 Recruiting
NCT06444815 2026-04-07
STEALTH-001
KaliVir Immunotherapeutics
Phase 1 Recruiting
NCT07170592 2026-04-07
A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients
Bionoxx Inc.
Phase 1 Not yet recruiting
NCT04303858 2026-04-01
A Study to Evaluate Safety and Anti-Tumor Activity of Eciskafusp Alfa (RO7284755) Alone or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors
Hoffmann-La Roche
Phase 1 Completed
NCT03074513 2026-03-11
Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT06302426 2026-01-16
Trial of INI-4001 in Patients With Advanced Solid Tumours
Inimmune Corporation
Phase 1 Recruiting
NCT06488716 2025-12-24
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7759065 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
Phase 1 Terminated
NCT04276376 2025-12-01
ARIANES
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Terminated
NCT05715281 2025-11-25
Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05434234 2025-11-10
A Study of YL201 in Patients With Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2 Recruiting
NCT04185883 2025-10-22
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
Amgen
Phase 1 Active not recruiting
NCT05109442 2025-08-20
Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers
Affimed GmbH
Phase 1/2 Terminated
NCT05487235 2025-07-03
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
Phase 1 Completed
NCT04975958 2025-06-22
Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors
Adlai Nortye Biopharma Co., Ltd.
Phase 1 Completed
NCT06719973 2025-06-17
Phase 1 Study of M9466 Combined With Carboplatin and Platinum-based Anticancer Therapy (DDRiver 521)
EMD Serono
Phase 1 Withdrawn
NCT04642365 2025-05-21
A Study to Evaluate the Safety and Tolerability of RO7296682 in Combination With Atezolizumab in Participants With Advanced Solid Tumors.
Hoffmann-La Roche
Phase 1 Terminated
NCT04996017 2025-03-13
AtezoMeso
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 3 Recruiting
NCT05907980 2025-03-06
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
Chugai Pharmaceutical
Phase 1 Recruiting
NCT06331598 2024-12-24
IMperator
Hoffmann-La Roche
Phase 2 Withdrawn
NCT06003621 2024-11-15
MoST-TAP
Omico
Phase 2 Recruiting
NCT03973333 2024-10-18
Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab
Immunocore Ltd
Phase 1/2 Withdrawn
NCT04185831 2024-08-22
MEGALiT
Uppsala University Hospital
Phase 2 Active not recruiting
NCT04480372 2024-07-01
SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II
Swiss Cancer Institute
Phase 2 Completed
NCT05765084 2024-05-16
Immuno-MESODEC
University Hospital, Antwerp
Phase 1/2 Recruiting
NCT02478099 2024-05-03
MPDL3280A-treatment-IST-UMCG
University Medical Center Groningen
Phase 2 Active not recruiting
NCT03650348 2024-04-22
PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors
Pieris Pharmaceuticals, Inc.
Phase 1 Completed
NCT04857138 2024-02-05
A Study to Evaluate Safety, Pharmacokinetics and Anti-Tumor Activity of RO7300490, as Single Agent or in Combination With Atezolizumab in Participants With Advanced Solid Tumors
Hoffmann-La Roche
Phase 1 Completed
NCT06090318 2023-10-19
Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss
Rain Oncology Inc
Phase 1/2 Withdrawn
NCT04471415 2023-06-12
Study to Investigate DRP-104 in Adults With Advanced Solid Tumors
Dracen Pharmaceuticals, Inc.
Phase 1/2 Terminated
NCT05809336 2023-04-12
Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors
Beijing Friendship Hospital
Phase 2/3 Completed
NCT03654833 2023-03-14
MiST
University of Leicester
Phase 2 Unknown
NCT05429866 2023-03-08
Immunological Variables Associated to ICI Toxicity in Cancer Patients
Jules Bordet Institute
Phase 2 Unknown
NCT02715531 2021-07-09
A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors
Hoffmann-La Roche
Phase 1 Completed
NCT03786419 2021-05-13
A Study of Atezolizumab in Unresectable or Advaced Malignant Pleural Mesothelioma
Health Pharma Professional Research
Phase 2 Withdrawn
NCT03264066 2021-05-11
A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid Tumors
Hoffmann-La Roche
Phase 2 Completed
NCT02541604 2020-02-25
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors
Hoffmann-La Roche
Phase 1/2 Terminated
NCT02650713 2020-02-12
A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors
Hoffmann-La Roche
Phase 1 Completed
NCT02350673 2020-01-18
A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors
Hoffmann-La Roche
Phase 1 Completed
NCT01988896 2019-12-17
Study of Atezolizumab in Combination With Cobimetinib in Participants With Locally Advanced or Metastatic Solid Tumors
Hoffmann-La Roche
Phase 1 Completed
NCT02304393 2019-12-13
A Study of Selicrelumab (RO7009789) in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors
Hoffmann-La Roche
Phase 1 Completed
NCT02471846 2019-10-22
A Study of GDC-0919 and Atezolizumab Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
Phase 1 Completed